Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Urologists Explore Treatments for Recurrent UTIs, the Financial Burden of UTIs and UTI Information on Social Media
CHICAGO , April 28, 2023 /PRNewswire/ — What is MV140 and how does it help prevent rUTI? How many women experience financial toxicity when getting treated for urinary incontinence? Can women trust information about UTIs on YouTube?
Researchers will be presenting these women's health study findings at the 118th Annual Scientific Meeting of the American Urological Association. Wai Lee, MD, Director of Female Pelvic Medicine and Reconstructive Surgery at the Smith Institute for Urology, will moderate a virtual press session featuring the following three abstracts.
J. Curtis Nickel, MD, from Queen's University, evaluated MV140, a novel bacterial sublingual vaccine for prevention of recurrent urinary tract infections. ",MV140 sublingual vaccine reduces risk of recurrent urinary tract infection (rUTI) in North American women: Results from the first North American clinical experience study.",
Benjamin Green, from Montefiore Medical Center, performed the first study to characterize financial toxicity associated with the treatment of urinary incontinence. ",Evaluation of Financial Toxicity Associated with Urinary Incontinence Treatment.",
Lynn Stothers, MD, from University of British Columbia, documented the quality, veracity, and comprehensiveness of recurrent UTI information on YouTube to increase health care workers' awareness of UTI-related content online. ",Misconceptions about women with recurrent urinary tract infection in YouTube educational videos, Incongruence with AUA guidelines - health equity findings.",
"Urinary incontinence and recurrent urinary tract infections are prevalent, yet impactful conditions that disproportionately affect women. For our media session, we wanted to highlight contemporary research on the financial toxicity of urinary incontinence treatment and share the promising results of a clinical trial evaluating a vaccine used to treat recurrent urinary tract," said Dr. Lee. "Another goal is to shed light on the misinformation encountered by the public related to recurrent urinary tract infections, by discussing a study on YouTube educational videos and their incongruence with the guidelines set out by the American Urological Association. We hope our viewers find our session informative and thought provoking."
NOTE TO REPORTERS: Presenting authors and moderators are available to discuss their findings. To arrange an interview with an expert, please contact the AUA Communications Team at Communications@AUAnet.org.
About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology and has nearly 24,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.
Media Contact:
Corey Del Bianco, Corporate Communications and Media Relations Manager
410-689-4033, cshegda@auanet.org
SOURCE American Urological Association